Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A role for IL-33–activated ILC2s in eosinophilic vasculitis
Maya E. Kotas, Jérémie Dion, Steven Van Dyken, Roberto R. Ricardo-Gonzalez, Claire J. Danel, Camille Taillé, Luc Mouthon, Richard M. Locksley, Benjamin Terrier
Maya E. Kotas, Jérémie Dion, Steven Van Dyken, Roberto R. Ricardo-Gonzalez, Claire J. Danel, Camille Taillé, Luc Mouthon, Richard M. Locksley, Benjamin Terrier
View: Text | PDF
Research Article Immunology

A role for IL-33–activated ILC2s in eosinophilic vasculitis

  • Text
  • PDF
Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease with poorly understood mechanisms. Here, we report that patients with EGPA have elevated levels of TSLP, IL-25, and soluble ST2, which are well-characterized cytokine “alarmins” that activate or modulate type 2 innate lymphoid cells (ILC2s). Patients with active EGPA have a concurrent reduction in circulating ILC2s, suggesting a role for ILC2s in the pathogenesis of this disease. To explore the mechanism of these findings in patients, we established a model of EGPA in which active vasculitis and pulmonary hemorrhage were induced by IL-33 administration in predisposed, hypereosinophilic mice. In this model, induction of pulmonary hemorrhage and vasculitis was dependent on ILC2s and signaling through IL4Rα. In the absence of IL4Rα or STAT6, IL-33–treated mice had less vascular leak and pulmonary edema, less endothelial activation, and reduced eotaxin production, cumulatively leading to a reduction of pathologic eosinophil migration into the lung parenchyma. These results offer a mouse model for use in future mechanistic studies of EGPA, and they suggest that IL-33, ILC2s, and IL4Rα signaling may be potential targets for further study and therapeutic targeting in patients with EGPA.

Authors

Maya E. Kotas, Jérémie Dion, Steven Van Dyken, Roberto R. Ricardo-Gonzalez, Claire J. Danel, Camille Taillé, Luc Mouthon, Richard M. Locksley, Benjamin Terrier

×

Figure 4

Deficiency of IL4Rα signaling protects from vasculitis in hypereosinophilic mice.

Options: View larger image (or click on image) Download as PowerPoint
Deficiency of IL4Rα signaling protects from vasculitis in hypereosinophi...
(A) BAL from IL-33–treated IL5Tg, STAT6–/– x IL5Tg, or IL4Rα–/– x IL5Tg. Representative of 4 or more mice/group. (B) Eosinophils in BAL of mice from A. Data are presented as ± SEM. ****P < 0.0001; **P < 0.01; *P < 0.05; ns = by 1-way ANOVA with Sidak post hoc testing. n = 2–4 mice/group. (C) ILC2s in BAL of mice from A. ***P < 0.001; *P < 0.05; ns = by 1-way ANOVA with Sidak post hoc testing. n = 2–4 mice/group. (D) H&E staining of lungs from representative IL-33–treated IL5Tg, STAT6–/– x IL5Tg or IL4Rα–/– x IL5Tg mice treated with IL-33, as shown in A–C (original magnification, ×10). Scale bars: 100 μm. (E) Histopathological scoring for infiltrates, (F) alveolitis, (G) giant cells, and (H) pulmonary capillaritis in ILC2del, STAT6–/–, or IL4Rα–/– with or without IL5Tg after saline or IL-33 treatment. ****P < 0.0001, ***P < 0.001, **P < 0.01; *P < 0.05 by 1-way ANOVA with Dunnett’s post hoc testing. n = 4–9 mice/group. Data are presented as ± SEM. BAL, bronchoalveolar lavage; ILC2s, type 2 innate lymphoid cells.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts